This study aimed to assess whether the expression of NRF2 and Peroxiredoxin 6 could serve as predictive biomarkers of tumor response to treatment (surgery combined with radiotherapy), as evaluated by the absence of tumor progression at 24 months. This evidence concerns the gene PRDX6 and neoplasm.